Spotlight On
β Any patient on a dopamine blocker may develop TD
Latest in Spotlight On
Until 2017, no FDA approved options existed for serious side effect of dopamine-blocking drugs
Clinicians need to rely on prescribing practices that minimize risk of development, says expert
With results that matter for patients, the mandate for testing is growing
Long-term treatment can present significant challenges
With results that matter for patients, the mandate for testing is growing
Long-term treatment can present significant challenges
More in Spotlight On
For high-risk patients, classic "watch and wait" may cede to early therapy
PCPs are "perfectly situated" to identify initial thinking changes of patients, expert says
HER2 blockade, PARP inhibitors, and other novel strategies
Not all patients are candidates for delandistrogene moxeparvovec
Emerging targets and treatment pathways in multiple myeloma
Young MS patients are at risk of irreversible disability accrual
Other JAK inhibitors, combinations, and novel therapies offer more hope for patients
Molecular testing is beginning to make a difference for patients
GLP-1 receptor agonists may be able to tackle the major modifiable risk factor
Earlier diagnosis may lead to improved long-term outcomes
Despite benefits, rotavirus vaccine uptake lags behind other childhood vaccines
Could quintuplet therapy be next?
